The survey results also showed an increasing willingness among Americans to receive the vaccine.
Nearly two-thirds of Americans are not satisfied with the rollout of the coronavirus disease 2019 (COVID-19) vaccine in the United States, according to results of a new Gallup poll.
However, 71% of Americans now say they are willing to be vaccinated, which is up from 65% in late December and the highest percentage on record. This figure also includes 62% who said they would receive the vaccine if it was available to them right now at no cost and 9% who say they have already received at least 1 dose.
According to the survey, 21% of respondents reported being “very dissatisfied” with the vaccination process. Thirty-four percent are satisfied, with 4% who are “very satisfied,” the results showed. Those who identified as Republican were evenly split on whether they reported being satisfied with the process, whereas Democrats (79%) and independents (63%) are largely dissatisfied.
Trending: Biden Administration to Ship COVID-19 Vaccines Directly to Pharmacies
The survey results also showed that:
Twenty-five percent of Americans in the survey reported concerns about the speedy timeline of development of the vaccine as a reason for their reluctance. However, this percentage has dropped 12 points since the question was previously asked in the fall. Additionally, 22% want to wait to confirm the vaccine is safe before receiving it, 16% said they do not trust vaccines in general, and 9% want to see how effective it is. Another 28% cited other reasons, which include misperceptions about the risk of COVID-19, concerns about adverse reactions, and a general distrust of the government.
Related: Understanding the COVID-19 Vaccine
Despite these concerns, the latest survey results demonstrate an increasing willingness among Americans to get vaccinated. As more doses become available, pharmacists can play a more critical role in allaying any residual concerns about the vaccines and encouraging individuals to receive them.
Reference
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.